Taro Pharmaceutical Industries P/E Ratio

Taro Pharmaceutical Industries posts a P/E ratio of 30.05. That is above the Healthcare sector average of 26.36. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a P/E ratio near 26.36 is typical. Taro Pharmaceutical Industries's 30.05 is higher that level. That is roughly 14.0% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Taro Pharmaceutical Industries's P/E ratio of 30.05 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.

Context for TARO's P/E ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 26.36), and (3) consistency with growth and profitability. This page covers the first two; Taro Pharmaceutical Industries's other metric pages and overview cover the third.

Judging Taro Pharmaceutical Industries against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in P/E ratio easier to interpret. Start with 30.05 here, then scan peer and history charts to see if the gap is persistent.